Volume, M. Market Value, $M. Shares Outstanding, M. EPS (TTM), -$ P/E Ratio (TTM), N/A. Dividend Yield, N/A. Latest Dividend, N/A. On average, Wall Street analysts predict that Ocugen's share price could reach $ by May 15, The average Ocugen stock price prediction forecasts a. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced. Stay up-to-date on Ocugen, Inc. Common Stock (OCGN) news with the latest updates, breaking headlines, news articles, and more from around the web at. The high in the last 52 weeks of Ocugen stock was According to the current price, Ocugen is % away from the week high. What are analysts forecasts.
Ocugen (NASDAQ:OCGN) will be releasing earnings before the market opens on Thursday, August 8, Zacks reports. (Nasdaq: OCGN), a biotechnology company focusing on gene and cell therapies and vaccines, has closed its public offering of 30,, common stock shares at. Ocugen's stock bounces after 'positive' results from COVID vaccine candidate in children as young as 2 years old. OCGN Ocugen · High. · Low. · Volume. M · Open. · Pre Close. · Turnover. M · Turnover Ratio. % · P/E (Static). Loss. Today's OCGN Stock Price for Ocugen Inc NASDAQ: OCGN stock plus other stock analyst insights, related news and more. Ocugen has a consensus price target of $ Q. What is the current price for Ocugen (OCGN)?. A. The stock price. Ocugen (OCGN) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering for its shares. Today's Biggest Pre-Market. In a direct offering, eye-drug developer Ocugen sold 3 million shares at $, 46% above Friday's close. The stock leaped on Monday. OCGN. Ocugen Inc ; Jun AM · 3 Penny Stocks Set to Make New Millionaires in (InvestorPlace) % ; AM · Ocugen, Inc. Announces First Patient. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Ocugen, Inc News & Analysis · Ocugen completes dosing in Stargardt disease trial · Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in.
Today's High: $; Today's Low: $; 52 Week High: $; 52 Week Low: $ Sign up to receive email alerts with the latest news from Ocugen. Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up. OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU for. Ocugen Inc stock news, updates & related news. Find out why Ocugen Inc's (OCGN) news sentiment is more negative in relation to stocks in the Healthcare. It's current price per share is approximately $ What are your Ocugen, Inc. (OCGN) stock predictions? 3 Wall Street. Ocugen Inc ; Previous Close: ; Open: ; Volume: 5,, ; 3 Month Average Trading Volume: ; Shares Out (Mil): Ocugen Inc (OCGN) has a Smart Score of 7 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund. OCGN Ocugen Inc. , $ $ (%). Today. Watchers, , Wk Low, $ Wk High, $ Market Cap, $M. Volume, , Discover real-time Ocugen, Inc. Common Stock (OCGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. The current price of OCGN is USD — it has decreased by −% in the past 24 hours. Watch Ocugen, Inc. stock price performance more closely on the chart.
Ocugen (OCGN) - Develops and commercializes therapies to address rare and underserved eye diseases. Get Ocugen Inc (OCGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Conference Call and Webcast Today at a.m. ET Actively dosing patients in OCU Phase 3 liMeliGhT clinical trial OCU preliminary safety and efficacy. View the real-time OCGN price chart on Robinhood and decide if you want to buy or sell commission Low today$ Open price. $ Open price$ Volume. OCGN Related stocks ; AMGN, , +% ; Amgen Inc ; REGN, 1,, +% ; Regeneron Pharmaceuticals.
OCGN vs Biotech Stocks ; $M · %, x, x ; $M · +%, x, x. Ocugen Inc (OCGN) share price today is $ Can Indians buy Ocugen Inc shares? Yes, Indians can invest in the Ocugen Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings. Current Year's Estimate, Median PE on CY Estimate, N/A. Next Fiscal Year Estimate, Median PE on Next FY Estimate, N/A. Stock Price Targets. High.